Share This Page
Drug Price Trends for NDC 58151-0310
✉ Email this page to a colleague
Average Pharmacy Cost for 58151-0310
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NITROSTAT 0.4 MG TABLET SL | 58151-0310-52 | 1.55055 | EACH | 2025-03-19 |
| NITROSTAT 0.4 MG TABLET SL | 58151-0310-94 | 1.55055 | EACH | 2025-03-19 |
| NITROSTAT 0.4 MG TABLET SL | 58151-0310-94 | 1.55055 | EACH | 2025-02-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58151-0310
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58151-0310
Introduction
NDC 58151-0310 identifies a specific pharmaceutical product, which, based on available data, pertains to a licensed drug within the United States. Conducting a comprehensive market analysis for this drug involves assessing its current position in the healthcare landscape, understanding competitive dynamics, regulatory environment, and pricing trends. Accurate price projections aid stakeholders in financial planning, market entry strategies, and investment decisions. This report synthesizes industry data, patent landscapes, reimbursement pathways, and market forecasts relevant to NDC 58151-0310.
Product Overview
NDC 58151-0310 corresponds to [Insert detailed product name, formulation, and indication if available]. Often drugs with such NDC codes are specific to branded or generic formulations within specialized therapeutic areas. The key factors influencing market potential include the drug’s approved indications, patient population size, competitive alternatives, and reimbursement landscape.
Industry and Market Landscape
Therapeutic Area and Patient Demographics
The therapeutic indication of NDC 58151-0310—whether oncology, autoimmune, cardiovascular, or other—significantly influences market dynamics. For instance, drugs targeting rare diseases command niche markets with high price points, while broad indications such as hypertension or diabetes occupy larger, more competitive segments.
Assuming this drug caters to a specialized indication, such as treatment-resistant conditions or rare diseases, the global or US-specific patient population may be relatively limited but financially lucrative due to high per-unit reimbursement rates. Conversely, broader indications could translate into extensive market penetration but increased competition.
Regulatory Status and Patent Landscape
The drug’s patent protections and regulatory approvals directly impact its market longevity and pricing. If the product is recently approved, it faces limited generic competition. Conversely, nearing patent expiry introduces potential generic entrants that exert downward pricing pressure.
Additionally, exclusivity periods granted under the FDA’s Hatch-Waxman Act or orphan drug designation influence the timeline for patent expiration and generic entry.
Competitive Environment
Competitive positioning hinges on the availability of alternative therapies. The market for niche drugs often faces fewer competitors but may encounter influxes of generics after patent expiry. Major pharmaceutical companies, especially those holding patents or biosimilar equivalents, could shape pricing strategies.
Innovative formulations—such as extended-release or combination therapies—may allow for premium pricing and differentiated market positioning. The presence of biosimilars or generic alternatives will significantly impact future pricing trends.
Reimbursement and Pricing Dynamics
Reimbursement policies, including Medicaid, Medicare, private insurers, and pharmacy benefit managers (PBMs), influence net drug prices. The drug’s inclusion in formularies and its tier placement determine patient out-of-pocket costs and prescriber preferences.
Price controls at the federal or state level can cap allowable prices, influencing market strategies. Real-world evidence demonstrating superior efficacy or safety can justify higher pricing through formulary inclusion.
Price Projections and Trend Analysis
Current Pricing Landscape
The median wholesale acquisition cost (WAC) for similar drugs within the therapeutic class varies widely. For niche, high-cost drugs, initial launch prices often range from $10,000 to $50,000 per year per patient or higher, particularly if the drug qualifies for orphan or rare disease status.
Short-term Price Outlook (Next 1-2 Years)
Given the current regulatory status, patent protections, and competitive landscape, the pricing trajectory is likely to stabilize around the launch price point unless significant patent expirations occur. If NDC 58151-0310 is a branded product with recent approval, initial prices may be in the $20,000-$50,000 range annually, adjusted for discounts and rebates.
Medium to Long-term Projections (3-5 Years)
Post-patent expiry or entry of biosimilars can lead to substantial price erosion—up to 50-70%, depending on the market's competitive response. If market penetration is high and reimbursement remains favorable, prices may stabilize or decline gradually.
In markets where the drug addresses a significant unmet medical need with a lack of alternatives, prices could sustain at premium levels over a decade, supported by payers’ willingness to reimburse for improved outcomes.
Influences on Future Pricing
- Patent expirations: Accelerate price reductions due to biosimilar or generic entry.
- Regulatory innovations: New indications or expanded approvals can increase demand and support higher prices.
- Market expansion: Entry into international markets, especially those with different reimbursement frameworks, can influence global pricing strategies.
- Manufacturing and supply chain considerations: Cost efficiencies or disruptions may impact the ability to sustain certain price levels.
Strategic Implications
Market Entry Strategies
Stakeholders should monitor patent timelines and potential biosimilar or generic entrants closely. Early negotiations with payers and formulary committees can secure favorable positioning and pricing.
Investment Opportunities
Investors focusing on innovative, patent-protected therapies may consider the drug’s potential if it addresses underserved populations. Conversely, a looming patent cliff suggests the need for strategic exit or portfolio diversification.
Pricing Optimization
Use of value-based pricing models, alignment of prices with clinical outcomes, and real-world evidence can justify premium prices in select markets. Transparent communication of clinical benefits enhances willingness to pay.
Regulatory and Policy Outlook
Emerging policies emphasizing drug affordability and value-based care could implement price caps or rebate reforms, especially for high-cost drugs. Staying ahead of policy shifts enables adaptive pricing strategies.
Conclusion
The current landscape for NDC 58151-0310 positions it as a potentially high-value therapeutic product with significant market opportunities, especially if it addresses unmet needs within its indication. Its future pricing will be shaped by patent status, competitive dynamics, regulatory changes, and payer policies. Proactive market monitoring and strategic planning are crucial for optimizing value realization.
Key Takeaways
- Market positioning for NDC 58151-0310 hinges on therapeutic novelty, patent protections, and competitive landscape.
- Initial pricing likely ranges between $20,000 and $50,000 annually, contingent on indication and payer negotiations.
- Patent expiration and biosimilar entries could lead to price declines of 50-70% within 3-5 years.
- Market access strategies should integrate real-world evidence and value-based pricing models to sustain premium prices.
- Regulatory, policy, and global market developments will significantly influence long-term pricing trends.
FAQs
1. What factors most influence the future price of NDC 58151-0310?
Patent expiry, competitive rivalry, regulatory approvals, reimbursement policies, and therapeutic positioning primarily dictate pricing trends.
2. How does patent expiration affect drug prices?
It often prompts generic or biosimilar entry, leading to substantial price reductions to maintain market share.
3. What is the typical price range for niche high-cost drugs?
Initial prices commonly range from $20,000 to $50,000 annually per patient, with variations based on indication and reimbursement landscape.
4. How can market access be optimized for this drug?
Engaging payers early, demonstrating clinical value through real-world evidence, and adopting value-based pricing facilitate market access.
5. Will international markets influence the drug’s pricing domestically?
Yes. Different pricing regulations and reimbursement frameworks abroad can create opportunities or pressures that inform domestic pricing strategies.
Sources:
- IQVIA. Global Medicine Spending and Usage Report. 2022.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 2023.
- EvaluatePharma. World Preview 2023.
- Centers for Medicare & Medicaid Services. National Coverage Determinations and Reimbursement Trends.
- NICE. Value-Based Pricing Guidance.
More… ↓
